To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology Inc. ("Puma Biotechnology") (NYSE: PBYI) between July 23, 2014 and May 13, 2015.
The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (a) the Company's New Drug Application filing would be for a positive early stage breast cancer indication, rather than the previously announced metastatic breast cancer; (b) Puma would need to submit additional safety data from preclinical carcinogenicity studies with its NDA filing, which Puma did not have; (c) the additional studies required would push the timelines for filing the NDA; and (d) the Company overstated results from its Phase III ExteNET Trial.
If you suffered a loss in Puma Biotechnology you have until August 3, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.